Sign in to fuzzto save your conversations, follow your research and come back anytime.
Sanjivani Paranteral
SectorHealthcare
The Quarter story
The two most recent quarterly results, compared side-by-side.
Export-led revenue growth and strong margins drive profitability, though rising costs and a shrinking nutraceutical segment require attention.
Revenue grew from ₹179 Cr in Q1 FY26 to ₹238.39 Cr in Q1 FY27 — driven by strong overseas demand
Nutraceuticals revenue collapsed from ₹12.1 Cr in Q2 FY26 to ₹0.18 Cr in Q1 FY27 — signaling a major segment slowdown
Export share expanded from 73.7% in Q1 FY26 to 90.50% in Q1 FY27 — making international markets the core growth engine
Employee costs climbed from ₹14.9 Cr in Q2 FY26 to ₹23.54 Cr in Q1 FY27 — reflecting aggressive hiring for expansion
EBITDA margin improved from 15.0% in Q1 FY26 to 18.01% in Q1 FY27 — showing better cost control and pricing power
Finance costs increased from ₹0.5 Cr in Q2 FY26 to ₹3.47 Cr in Q1 FY27 — adding pressure from higher debt servicing
Injectables revenue rose from ₹89.9 Cr in Q1 FY26 to ₹110.12 Cr in Q1 FY27 — maintaining its position as the top revenue driver
Depreciation jumped from ₹1.6 Cr in Q1 FY26 to ₹6.52 Cr in Q1 FY27 — indicating heavy capital investments being amortized
Profit after tax recovered from ₹16.4 Cr in Q2 FY26 to ₹24.91 Cr in Q1 FY27 — confirming steady bottom-line delivery
Other expenses rose from ₹14.2 Cr in Q2 FY26 to ₹23.92 Cr in Q1 FY27 — pointing to rising operational overheads
